On the morning of October 27, the First Chinese Summit for Pharmaceutical Quality was held in YRPG. The event was themed "Improve pharmaceutical quality, safeguard people's health and promote sustainable growth of medical industry", co-hosted by Chinese Medical Newspaper, China Quality Association for Pharmaceuticals and YRPG, and was attended by over 200 people including leaders from CFDA, provincial and municipal drug administrations and agencies and "AAA" hospitals. The summit called for the accelerated restructuring of pharmaceutical industry and enhancing quality standards to guarantee people's safe use of drugs.
Jiao Hong, Deputy Head of CFDA, Zhang Heyong, State Counselor, He Rong, member of Taizhou Party Standing Committee, Hu Xiaoshu, Head of JFDA, and Fang Xianye, General Editor of Chinese Medicine Newspaper also attended the summit. Xu Jingren delivered the welcome speech. Weng Xintai, YRGP's general engineer, briefed about the company's experience and practice on quality control and safety of drugs during the summit.
In recent years, there's increasingly deeper public concern on drug safety. People's demand on drug efficiency and safety was growing along with the improvement of living standards and social-economic progress. Aging population, changes of disease patterns and new and frequent epidemics pose challenges on drug efficiency and safety. At the same time, the rapid growth of pharmaceutical industry, the accelerating industrial restructuring, and wider application of new technologies in the industry also pose higher demand on safety surveillance. Under such new circumstances, the summit was held, inviting representatives from all quarters of the industry to discuss how to better safeguard people's health, promote a sound development of the industry and improve China's overall drug safety.
Jiao Hong said: "it is responsible  for both drug agencies and pharmaceutical companies to strengthen safety control on drugs and enhance China's overall drug safety. The recent incidents of tainted drugs show the loss of integrity on some pharmaceutical companies, and also pose greater challenges for drug administrations and agencies. Therefore, in addition to strengthen safety control on drugs, companies should also strengthen themselves, guarantee drug quality at the beginning of production, ensure the 100% standards to safeguard drug quality and health of people." Jiao Hong expressed his appreciation of YRPG's long-term principles of "Benefit the public through quality products and innovation". He also praised YRPG's openness to "quality judges" and establishment of training base of National Institute for Food and Drug Control.
Zhang Heyong reviewed the current situation of China's quality control from medical companies. He praised YRPG for its QC team activities, its commitment to mobilizing the staff on quality control, its winning the most prizes in national pharmaceutical industry QC for eight consecutive years and as the Dream Team in China's pharmaceutical industry. He said YRPG was a banner in QC of national pharmaceutical industry.
Xu Jingren said: "We will continue to stick to 'benefit the public through quality products' and relentless pursuit of better quality of our products. Faced with ever fiercer competition, YRPG will work to win market with its quality and efficient products, win people's trust and deliver a leap-forward of its own transformation. In the future, we will seize the opportunity brought by the opening of TCM Quality Control Research Center (which is the only key in lab featuring international cooperation that has met GMP requirements and is in cooperation with State Administration of Traditional Chinese Medicine), and continue to improve drug standards and catch up with US GMP and EU GMP. At the same time, we will work with European Pharmacopoeia to launch the registry of herbal drugs in EU and formulation of standards for TCMs. We will work hard to turn YRPG into an international pharmaceutical enterprise."
In the afternoon, representatives discussed issues such as "how to strengthen surveillance on drugs", "how to use drugs safely", "how to stick to 'Quality as priority and price be reasonable' in inviting bids", "how to strengthen safe production of drugs" and "how to raise standards on drug quality". On the issue of integrity of pharmaceutical companies, CQAP called for stepping up industrial restructuring, promoting development through better quality, substantially improving quality and efficiency of drugs, safeguarding public health and drug safety and reputation of pharmaceutical industry, so that drug quality is no longer a concern among the general public and drug administrations.
During the meeting, leaders and representatives visited workshops and QC centers. YRPG's scale, independent research and development capacity, automatic production line, high-end QC instruments and quality products gave them a more specific and concrete understanding of YRPG's principle of "Benefit the public through quality products and innovation". Representatives from medical systems expressed willingness to cooperate with YRPG so that YRPG could benefit more people with its quality and efficient products.
(by Zhuang Yichun and Liu Liangming)